Treatment options after progression on anti–PD-1 and BRAF/MEK inhibitors have been limited but TIL therapy has expanded metastatic melanoma treatment.
Health Professionals
Longer Time Until Recurrence Associated With Better Melanoma Outcomes
An expert explains study findings that associate a longer time until postsurgical melanoma recurrence with improved progression and survival.
Anti-CTAg Antibodies Identified in Stage I, II Melanoma
WEDNESDAY, Oct. 2, 2024 (HealthDay News) — Circulating antibodies against cancer-testis antigens (CTAgs) are found in stage I and stage II melanoma plasma samples, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. 25 to 28 in Amsterdam.
Anti-Cancer Antibodies May Aid Early Melanoma Detection
Australian researchers have shown that circulating antibodies against tumor antigens can be used as an accurate biomarker for the early detection of melanoma.